Top Page
Everest Medicines Ltd.
(1952)
Everest Medicines Ltd. (1952) vs. iShares MSCI Hong Kong ETF (EWH)
Everest Medicines Ltd. Business Overview & Revenue Model
Everest Medicines Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 851.28M | 706.68M | 125.93M | 12.79M | 54.00K | 0.00 |
| Gross Profit | 597.21M | 528.89M | 91.52M | 8.15M | 31.00K | 0.00 |
| EBITDA | -276.68M | -670.04M | -744.63M | -198.91M | -972.78M | -683.03M |
| Net Income | -658.75M | -1.04B | -844.46M | -247.28M | -1.01B | -5.68B |
Balance Sheet | ||||||
| Total Assets | 4.93B | 4.96B | 5.77B | 6.61B | 6.65B | 7.48B |
| Cash, Cash Equivalents and Short-Term Investments | 1.59B | 1.60B | 2.35B | 1.65B | 2.64B | 4.48B |
| Total Debt | 708.72M | 575.61M | 510.63M | 534.64M | 485.03M | 447.33M |
| Total Liabilities | 1.01B | 886.05M | 804.10M | 960.25M | 753.83M | 636.11M |
| Stockholders Equity | 3.93B | 4.07B | 4.97B | 5.65B | 5.89B | 6.84B |
Cash Flow | ||||||
| Free Cash Flow | -205.84M | -744.92M | -1.04B | -1.59B | -1.71B | -991.83M |
| Operating Cash Flow | -181.47M | -679.51M | -769.19M | -1.16B | -729.94M | -471.90M |
| Investing Cash Flow | 423.71M | 974.40M | 752.50M | -1.03B | -975.82M | -519.93M |
| Financing Cash Flow | 171.64M | 37.80M | 10.10M | -25.31M | -76.51M | 5.64B |
Everest Medicines Ltd. Technical Analysis
Everest Medicines Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$11.00B | 14.47 | 6.69% | 4.28% | -8.49% | -9.46% | |
52 Neutral | HK$17.44B | -82.29 | -3.36% | ― | 58.24% | 38.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$14.32B | -18.15 | -15.75% | ― | 102.73% | 38.42% | |
44 Neutral | HK$9.19B | -15.58 | -42.46% | ― | 1219.19% | 25.15% | |
41 Neutral | HK$16.21B | -54.55 | -8.79% | ― | 964.40% | 65.90% | |
40 Underperform | HK$9.20B | -43.25 | -21.42% | ― | 240.05% | -140.09% |
Everest Medicines Ltd. Corporate Events
Everest Medicines Limited has announced a delay in sending a shareholder circular relating to its continuing connected transactions under a Commercialization Service Agreement. The circular, which will include details of the agreement, recommendations from the Independent Board Committee, and advice from an Independent Financial Adviser ahead of an extraordinary general meeting, was originally expected by 16 January 2026 but will now be published on or before 4 February 2026 due to additional time needed to prepare and finalize the information, potentially shifting the timeline for shareholder review and approval of the transaction.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines chairman and executive director Yifang Wu has increased his stake in the company by purchasing 30,000 shares on the open market on 31 December 2025 for about HK$1.14 million, at an average price of roughly HK$37.98 per share. The board said the on-market share purchase reflects Wu’s strong confidence in the company’s long-term prospects and development, although it cautioned existing shareholders and potential investors to exercise care when trading the stock.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines has responded to the approval of a generic version of its kidney disease drug NEFECON in China by stressing that NEFECON remains protected under a valid Chinese patent until May 2029, with the patent duly registered on the national platform for marketed drugs. Citing China’s Patent Law and the rules governing early settlement of drug patent disputes, the company warned that any manufacture, sale, promotion or import of products infringing this patent before its expiry would constitute infringement, and reminded generic applicants who have pledged not to market before patent expiry that they must honor this commitment; Everest pledged to take lawful action against suspected violations while reiterating its broader stance that robust IP enforcement is critical to fair competition, sustained innovation and continued patient access to innovative therapies in China.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced a significant increase in shareholding by its directors and a substantial shareholder, CBC Group. This move, involving a purchase of shares worth over HK$38 million, reflects strong confidence in the company’s future prospects and long-term development, potentially impacting its market positioning positively.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has announced a Commercialization Service Agreement with Hasten, under which its subsidiary will provide commercialization services for certain products in China. This agreement, effective from December 11, 2025, will initially last for three years with automatic renewals. The subsidiary will handle various services including distribution, marketing, and sales forecasting. A deposit of RMB100,000,000 will be paid to Hasten, refundable based on sales targets. This agreement reflects Everest Medicines’ strategic focus on expanding its market presence in China.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board also oversees three committees: audit, remuneration, and nomination, with specific directors assigned to each committee. This announcement provides clarity on the leadership structure of the company, potentially impacting its governance and strategic direction.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has entered into an agreement with Visara, Inc. to develop and commercialize VIS-101, a novel bifunctional biologic, in Greater China and other Asian markets. This strategic collaboration allows Everest Medicines to expand into the ophthalmology sector, adding a commercially attractive asset to its late-stage product pipeline, potentially enhancing its market positioning and addressing significant unmet medical needs in the region.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.